Pfizer, BMS report Phase II clotting trial success
More on the clotting drug race: Bristol-Myers Squibb and Pfizer announced that their oral anti-clotting therapy--apixaban--demonstrated comparability to the current standard of care that relies on an injectable combined with a drug that includes warfarin. The experimental pill hit its endpoints in a mid-stage study for the rates of blood clots and dangerous bleeding. The researchers say that a comparable therapy would allow patients to bypass a standard approach that includes harsh side effects and regular injections. Apixaban doesn't require close monitoring or dose adjustments.
- read the report from CNNMoney
Related Article:
Pfizer partners with BMS in $1B deal. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
